Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Biopharmaceutics and Pharmacokinetics: Overview01:28

Biopharmaceutics and Pharmacokinetics: Overview

Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the appropriate...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
Bioequivalence: Overview01:16

Bioequivalence: Overview

Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>In vitro</i> and <i>in vivo</i> efficacy of the Active Oligo Skin complex™, a new active ingredient processed from seawater, on multiple parameters of atopic skin.

Skin health and disease·2025
Same author

Lyotropic liquid crystal emulsions of LAVR-289: Influence of internal mesophase structure on cytotoxicity and in-vitro antiviral activity.

International journal of pharmaceutics·2024
Same author

Decontamination of Actinide-contaminated Injured Skin with Ca-DTPA Products Using an Ex Vivo Rat Skin Model.

Health physics·2024
Same author

Review of the PRIODAC project on thyroid protection from radioactive iodine by repeated iodine intake in individuals aged 12.

European thyroid journal·2024
Same author

Sensitivity of Legionella pneumophila to phthalates and their substitutes.

Scientific reports·2023
Same author

Effect of Phthalates and Their Substitutes on the Physiology of <i>Pseudomonas aeruginosa</i>.

Microorganisms·2022

Related Experiment Video

Updated: Jun 16, 2026

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

Container-content compatibility studies: a pharmaceutical team's integrated approach.

Alda Laschi1, Natacha Sehnal, Antoine Alarcon

  • 1French Society of Pharmaceutical Science and Technology (SFSTP) Working Group on Container-Content Interaction, 106 rue Monge, Paris, France. Alda.Laschi@sanofipasteur.com

PDA Journal of Pharmaceutical Science and Technology
|January 22, 2010
PubMed
Summary
This summary is machine-generated.

Container-content compatibility studies are crucial for pharmaceutical market authorization. This research proposes a standardized approach, focusing on toxicity, to ensure drug quality and patient safety in packaging interactions.

More Related Videos

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

Related Experiment Videos

Last Updated: Jun 16, 2026

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

Area of Science:

  • Pharmaceutical Science
  • Materials Science
  • Regulatory Affairs

Background:

  • Container-content compatibility studies are essential for new drug submissions and packaging changes.
  • Existing regulatory guidelines from the USA, Europe, and Japan lack precision, leading to inconsistent implementation.
  • The French Society of Pharmaceutical Science and Technology (SFSTP) formed a working group to address these inconsistencies.

Purpose of the Study:

  • To propose standardized guidance for container-content interaction studies.
  • To align guidance with both European and US regulatory requirements.
  • To facilitate consistent and standardized data submission by the pharmaceutical industry.

Main Methods:

  • Evaluation of drug product quality through stability studies.
  • Assessment of drug product safety using stability studies and toxicity testing (cytotoxicity).
  • Utilizing migration tests to identify interaction components when necessary, but emphasizing toxicity as the primary safety indicator.

Main Results:

  • Drug product quality is assessed via stability studies.
  • Patient safety is critically dependent on toxicity testing, with stability studies providing partial safety insights.
  • Migration tests are secondary to toxicity assessment for safety evaluation.

Conclusions:

  • A decision tree, prioritizing toxicity assessment, is proposed to guide pharmaceutical companies.
  • This approach aims to ensure consistent and robust container-content interaction studies.
  • The proposed guidance supports pharmaceutical companies in their regulatory filings for packaging compatibility.